Rimonbant shows promise in addressing multiple risk factors

reduced plasma insulin levels and the changed size of LDL particles, we now may have a drug that targets the most frequent cause of clustering risk factors."


A multi-center, double-blind, placebo-controlled study, RIO-Lipids enrolled 1,036 obese patients with dyslipidemia and a BMI between 27 and 40 kg/m2. Patients were randomized into three treatment groups receiving either a daily, fixed dose of 5mg or 20mg of rimonabant or placebo along with a reduced calorie diet for one year.

Patients treated for one year with rimonabant 20mg lost almost 20 lbs (8.6 kg) vs. a loss of only 5 lbs (2.4 kg) on placebo (p<0.001). Nearly three-fourths (72.9%) of these patients treated for a year with rimonabant 20mg lost more than 5% of their body weight vs. placebo (p<0.001) while nearly half (44.3%) lost in excess of 10% of their body weight vs. placebo (p<0.001). While weight loss was the primary endpoint, a waist circumference reduction of 3.4 inches (9.1 cm) in patients completing a year of treatment on rimonabant 20 mg was statistically significant (p<0.001 vs. placebo).

Researchers also designed the RIO-Lipids study to determine if rimonabant, in a group of overweight/obese patients at risk for cardiovascular disease, could improve important factors such as lipid profile, glucose metabolism and other features of the metabolic syndrome. Results show that both the 5 mg and 20 mg doses of rimonabant significantly improved two important indicators of cardiovascular risk, HDL-cholesterol and triglycerides vs. placebo. The patients treated for a year in the 20 mg group achieved an average 23% increase (p<0. 001 vs. placebo) in HDL-cholesterol and a reduction of 15% in triglycerides (p<9x10-5 vs. placebo).

No difference in LDL-cholesterol was observed between rimonabant and placebo. However, rimonabant 20mg delivered positive changes in LDL particle size, a known indicator of atherogenic risk. In patient

Contact: Glenn Lehrman

Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
Cached News: